BORON Molecular, a company wholly owned by Western Australian listed biotechnology investment company Xceed Biotechnology, has been granted a US and European Patent.
Boron head of research and development Seb Marcuccio said the protection granted by the patent would allow the company to generate a large number of new products of interest to the pharmaceutical and biotechnology industries.
The company provides leading pharmaceutical and biotech companies with small molecules to enhance their drug discovery programs.
Its proprietary chemistry expertise is in the creation of organoboron compounds that help the synthesis and scale up of potential drug candidates.